CRS has rarely been reported with evorpacept (N = 1 patient with reversible grade 3 CRS) and pembrolizumab but not with cetuximab, and increased cytokine secretion has been observed in preclinical models of combined CD47 and PD-L1 inhibition (26, 65, 71–73). This evidence concerns the gene CD47 and congenital rubella syndrome.